TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Biopsy
Female
Humans
Middle Aged
Nanoparticles
Paclitaxel
Receptors, TNF-Related Apoptosis-Inducing Ligand
Retreatment
Treatment Outcome
Triple Negative Breast Neoplasms

authors with profiles

Rita Nanda